mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (tnf-α) and other pro-inflammatory cytokines. mymd-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective tnf-α blocking drugs, and aging and longevity. supera-cbd is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (cbd) that targets numerous key receptors including cb2 and opioid receptors and inhibits monoamine oxidase. supera-cbd is being developed to address the rapidly growing cbd market that includes fda approved drugs and cbd products not currently regulated as a drug.
Company profile
Ticker
MYMD
Exchange
Website
CEO
Howard Yeaton
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Akers Biosciences Inc, Akers Biosciences, Inc.
SEC CIK
Corporate docs
Subsidiaries
Akers Acquisition Sub, Inc. • Bout Time Marketing Corporation • XYZ Merger Sub Inc. ...
MYMD stock data
Latest filings (excl ownership)
8-K/A
Amendments to Articles of Incorporation or Bylaws
26 Mar 24
8-K
Entry into a Material Definitive Agreement
7 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
13 Feb 24
8-K
Regulation FD Disclosure
6 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
19 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Oct 23
8-K
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4 Oct 23
8-K
Departure of Directors or Certain Officers
8 Sep 23
Latest ownership filings
SC 13G
Global X Management CO LLC
14 Feb 24
SC 13G/A
Iroquois Capital Management, LLC
14 Feb 24
4
Paul Rivard
24 Aug 23
4
Paul Rivard
18 Aug 23
4
Christopher C Chapman JR
9 Jun 23
4
Adam Kaplin
9 Jun 23
4
Jude Uzonwanne
9 Jun 23
4
Christopher C Schreiber
9 Jun 23
4
Joshua Silverman
9 Jun 23
4
CRAIG EAGLE
9 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 298.32 k | 298.32 k | 298.32 k | 298.32 k | 298.32 k | 298.32 k |
Cash burn (monthly) | (no burn) | 967.33 | (no burn) | 678.08 k | 1.05 mm | 1.11 mm |
Cash used (since last report) | n/a | 5.78 k | n/a | 4.05 mm | 6.29 mm | 6.62 mm |
Cash remaining | n/a | 292.54 k | n/a | -3.75 mm | -5.99 mm | -6.32 mm |
Runway (months of cash) | n/a | 302.4 | n/a | -5.5 | -5.7 | -5.7 |
Institutional ownership, Q3 2023
16.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 51 |
Opened positions | 12 |
Closed positions | 9 |
Increased positions | 11 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 2.51 bn |
Total shares | 8.38 mm |
Total puts | 185.40 k |
Total calls | 44.60 k |
Total put/call ratio | 4.2 |
Largest owners | Shares | Value |
---|---|---|
Caroline C Williams | 3.75 mm | $9.26 mm |
Vanguard | 1.46 mm | $863.31 mm |
Mirae Asset Global Investments | 940.60 k | $556.84 mm |
Intracoastal Capital | 364.96 k | $2.21 mm |
Geode Capital Management | 291.23 k | $172.44 mm |
BLK Blackrock | 207.16 k | $122.64 mm |
Praetorian Wealth Management | 200.00 k | $118.40 mm |
Cambria Investment Management | 171.57 k | $101.57 mm |
Susquehanna International | 135.61 k | $80.28 mm |
STT State Street | 120.25 k | $71.19 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Aug 23 | Paul Rivard | Common stock | Buy | Acquire P | No | No | 1.11 | 150,000 | 166.50 k | 400,000 |
17 Aug 23 | Paul Rivard | Common stock | Buy | Acquire P | No | No | 1.1232 | 25,000 | 28.08 k | 250,000 |
7 Jun 23 | Jude Uzonwanne | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 150,000 | 249.00 k | 150,000 |
7 Jun 23 | Craig Eagle | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 475,000 | 788.50 k | 475,000 |
7 Jun 23 | Silverman Joshua | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 200,000 | 332.00 k | 200,000 |
News
MyMD Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement For Continued Listing
5 Mar 24
MyMD Pharmaceuticals Announces 1-For-30 Reverse Stock Split To Maintain Nasdaq Listing
13 Feb 24
12 Health Care Stocks Moving In Thursday's After-Market Session
1 Feb 24
12 Health Care Stocks Moving In Friday's After-Market Session
26 Jan 24
12 Health Care Stocks Moving In Thursday's After-Market Session
25 Jan 24